Application of phage therapy: Synergistic effect of phage EcSw (ΦEcSw) and antibiotic combination towards antibiotic‐resistant Escherichia coli
Bacteriophage therapy is acknowledged as a potential tool to prevent or treat multidrug‐resistant bacterial infections. In this study, our major focus was on the bacteriolytic activity of phage EcSw (ΦEcSw) against the emergence of the clinically important Escherichia coli Sw1 and E. coli O157:H7. T...
Gespeichert in:
| Veröffentlicht in: | Transboundary and emerging diseases 2020-11, Vol.67 (6), p.2809-2817 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2817 |
|---|---|
| container_issue | 6 |
| container_start_page | 2809 |
| container_title | Transboundary and emerging diseases |
| container_volume | 67 |
| creator | Easwaran, Maheswaran De Zoysa, Mahanama Shin, Hyun‐Jin |
| description | Bacteriophage therapy is acknowledged as a potential tool to prevent or treat multidrug‐resistant bacterial infections. In this study, our major focus was on the bacteriolytic activity of phage EcSw (ΦEcSw) against the emergence of the clinically important Escherichia coli Sw1 and E. coli O157:H7. The amount of the antibiotics was changed in a concentration‐dependent manner, and the ΦEcSw susceptibility to antibiotics was determined. The kanamycin and chloramphenicol inhibited the titre of phage, but ampicillin did not show phage inhibition. Though the kanamycin and chloramphenicol controlled the growth of Sw1 in a concentration‐dependent manner, the ampicillin did not due to the resistance. The combined activity of the ΦEcSw with antibiotics (kanamycin and chloramphenicol) compared with the antibiotics alone showed significant lytic activity p |
| doi_str_mv | 10.1111/tbed.13646 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2407312322</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2468491270</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3936-45a035ac78eabad385063b830ed51cc814afa02f50cb9cc6c74cfbb342e18b6c3</originalsourceid><addsrcrecordid>eNp9kctKxDAUhoMo3jc-gBTcqDCaW9PWnZfxAoILdV2S09SJdJqadBhm5yOID-Hj-BA-iRk7o-LCQDjh5DtfAj9CWwQfkLAOW6WLA8IEFwtolaQi7hGR0sXvc8JX0Jr3jxgLnIl4Ga0wymOWYb6KXo-bpjIgW2PryJZRM5APOmoH2slmchTdTmrtHoxvDUS6LDW0P1AfbsfR7vvbtO5Fsi7Cbo0ydgqDHSpTd9rWjqUr_K_rj-cXp33QhlbU9xCeMzAwMoxVZgMtlbLyenNW19H9ef_u9LJ3fXNxdXp83QOWMdHjscQslpCkWipZsDTGgqmUYV3EBCAlXJYS0zLGoDIAAQmHUinGqSapEsDW0W7nbZx9Gmnf5kPjQVeVrLUd-ZxynDBCGaUB3fmDPtqRq8PvAiVSnhGa4EDtdxQ4673TZd44M5RukhOcT5PKp0nlX0kFeHumHKlh6M7ReTQBIB0wNpWe_KPK7076Z530E1lUof4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2468491270</pqid></control><display><type>article</type><title>Application of phage therapy: Synergistic effect of phage EcSw (ΦEcSw) and antibiotic combination towards antibiotic‐resistant Escherichia coli</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><creator>Easwaran, Maheswaran ; De Zoysa, Mahanama ; Shin, Hyun‐Jin</creator><creatorcontrib>Easwaran, Maheswaran ; De Zoysa, Mahanama ; Shin, Hyun‐Jin</creatorcontrib><description>Bacteriophage therapy is acknowledged as a potential tool to prevent or treat multidrug‐resistant bacterial infections. In this study, our major focus was on the bacteriolytic activity of phage EcSw (ΦEcSw) against the emergence of the clinically important Escherichia coli Sw1 and E. coli O157:H7. The amount of the antibiotics was changed in a concentration‐dependent manner, and the ΦEcSw susceptibility to antibiotics was determined. The kanamycin and chloramphenicol inhibited the titre of phage, but ampicillin did not show phage inhibition. Though the kanamycin and chloramphenicol controlled the growth of Sw1 in a concentration‐dependent manner, the ampicillin did not due to the resistance. The combined activity of the ΦEcSw with antibiotics (kanamycin and chloramphenicol) compared with the antibiotics alone showed significant lytic activity p < .001). In addition, phage‐based therapy was evaluated for controlling the multidrug‐resistant E. coli Sw1 and E. coli O157:H7 in zebrafish and BALB/c mice, respectively. Our results provide novel advantages of phage therapy and phage–antibiotic therapy to control antibiotic‐resistant bacteria.</description><identifier>ISSN: 1865-1674</identifier><identifier>EISSN: 1865-1682</identifier><identifier>DOI: 10.1111/tbed.13646</identifier><identifier>PMID: 32453904</identifier><language>eng</language><publisher>Germany: Hindawi Limited</publisher><subject>Ampicillin ; Ampicillin - therapeutic use ; Animals ; Anti-Bacterial Agents - therapeutic use ; Antibiotics ; Bacterial diseases ; Bacteriophages - physiology ; Chloramphenicol ; Chloramphenicol - therapeutic use ; Chloromycetin ; Combined Modality Therapy ; Drug Resistance, Multiple, Bacterial - drug effects ; E coli ; Escherichia coli ; Escherichia coli Infections - drug therapy ; Escherichia coli Infections - veterinary ; Escherichia coli O157 - drug effects ; Kanamycin ; Kanamycin - therapeutic use ; Mice ; Mice, Inbred BALB C ; Microbial Sensitivity Tests ; Microbial Viability - drug effects ; Phage Therapy - veterinary ; Phages ; phage‐based therapy ; Synergistic effect ; Therapy ; Zebrafish ; ΦEcSw</subject><ispartof>Transboundary and emerging diseases, 2020-11, Vol.67 (6), p.2809-2817</ispartof><rights>2020 Blackwell Verlag GmbH</rights><rights>2020 Blackwell Verlag GmbH.</rights><rights>Copyright © 2020 Blackwell Verlag GmbH</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3936-45a035ac78eabad385063b830ed51cc814afa02f50cb9cc6c74cfbb342e18b6c3</citedby><cites>FETCH-LOGICAL-c3936-45a035ac78eabad385063b830ed51cc814afa02f50cb9cc6c74cfbb342e18b6c3</cites><orcidid>0000-0002-6805-4924</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ftbed.13646$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Ftbed.13646$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32453904$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Easwaran, Maheswaran</creatorcontrib><creatorcontrib>De Zoysa, Mahanama</creatorcontrib><creatorcontrib>Shin, Hyun‐Jin</creatorcontrib><title>Application of phage therapy: Synergistic effect of phage EcSw (ΦEcSw) and antibiotic combination towards antibiotic‐resistant Escherichia coli</title><title>Transboundary and emerging diseases</title><addtitle>Transbound Emerg Dis</addtitle><description>Bacteriophage therapy is acknowledged as a potential tool to prevent or treat multidrug‐resistant bacterial infections. In this study, our major focus was on the bacteriolytic activity of phage EcSw (ΦEcSw) against the emergence of the clinically important Escherichia coli Sw1 and E. coli O157:H7. The amount of the antibiotics was changed in a concentration‐dependent manner, and the ΦEcSw susceptibility to antibiotics was determined. The kanamycin and chloramphenicol inhibited the titre of phage, but ampicillin did not show phage inhibition. Though the kanamycin and chloramphenicol controlled the growth of Sw1 in a concentration‐dependent manner, the ampicillin did not due to the resistance. The combined activity of the ΦEcSw with antibiotics (kanamycin and chloramphenicol) compared with the antibiotics alone showed significant lytic activity p < .001). In addition, phage‐based therapy was evaluated for controlling the multidrug‐resistant E. coli Sw1 and E. coli O157:H7 in zebrafish and BALB/c mice, respectively. Our results provide novel advantages of phage therapy and phage–antibiotic therapy to control antibiotic‐resistant bacteria.</description><subject>Ampicillin</subject><subject>Ampicillin - therapeutic use</subject><subject>Animals</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Bacterial diseases</subject><subject>Bacteriophages - physiology</subject><subject>Chloramphenicol</subject><subject>Chloramphenicol - therapeutic use</subject><subject>Chloromycetin</subject><subject>Combined Modality Therapy</subject><subject>Drug Resistance, Multiple, Bacterial - drug effects</subject><subject>E coli</subject><subject>Escherichia coli</subject><subject>Escherichia coli Infections - drug therapy</subject><subject>Escherichia coli Infections - veterinary</subject><subject>Escherichia coli O157 - drug effects</subject><subject>Kanamycin</subject><subject>Kanamycin - therapeutic use</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Microbial Sensitivity Tests</subject><subject>Microbial Viability - drug effects</subject><subject>Phage Therapy - veterinary</subject><subject>Phages</subject><subject>phage‐based therapy</subject><subject>Synergistic effect</subject><subject>Therapy</subject><subject>Zebrafish</subject><subject>ΦEcSw</subject><issn>1865-1674</issn><issn>1865-1682</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctKxDAUhoMo3jc-gBTcqDCaW9PWnZfxAoILdV2S09SJdJqadBhm5yOID-Hj-BA-iRk7o-LCQDjh5DtfAj9CWwQfkLAOW6WLA8IEFwtolaQi7hGR0sXvc8JX0Jr3jxgLnIl4Ga0wymOWYb6KXo-bpjIgW2PryJZRM5APOmoH2slmchTdTmrtHoxvDUS6LDW0P1AfbsfR7vvbtO5Fsi7Cbo0ydgqDHSpTd9rWjqUr_K_rj-cXp33QhlbU9xCeMzAwMoxVZgMtlbLyenNW19H9ef_u9LJ3fXNxdXp83QOWMdHjscQslpCkWipZsDTGgqmUYV3EBCAlXJYS0zLGoDIAAQmHUinGqSapEsDW0W7nbZx9Gmnf5kPjQVeVrLUd-ZxynDBCGaUB3fmDPtqRq8PvAiVSnhGa4EDtdxQ4673TZd44M5RukhOcT5PKp0nlX0kFeHumHKlh6M7ReTQBIB0wNpWe_KPK7076Z530E1lUof4</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Easwaran, Maheswaran</creator><creator>De Zoysa, Mahanama</creator><creator>Shin, Hyun‐Jin</creator><general>Hindawi Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6805-4924</orcidid></search><sort><creationdate>202011</creationdate><title>Application of phage therapy: Synergistic effect of phage EcSw (ΦEcSw) and antibiotic combination towards antibiotic‐resistant Escherichia coli</title><author>Easwaran, Maheswaran ; De Zoysa, Mahanama ; Shin, Hyun‐Jin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3936-45a035ac78eabad385063b830ed51cc814afa02f50cb9cc6c74cfbb342e18b6c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Ampicillin</topic><topic>Ampicillin - therapeutic use</topic><topic>Animals</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Bacterial diseases</topic><topic>Bacteriophages - physiology</topic><topic>Chloramphenicol</topic><topic>Chloramphenicol - therapeutic use</topic><topic>Chloromycetin</topic><topic>Combined Modality Therapy</topic><topic>Drug Resistance, Multiple, Bacterial - drug effects</topic><topic>E coli</topic><topic>Escherichia coli</topic><topic>Escherichia coli Infections - drug therapy</topic><topic>Escherichia coli Infections - veterinary</topic><topic>Escherichia coli O157 - drug effects</topic><topic>Kanamycin</topic><topic>Kanamycin - therapeutic use</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Microbial Sensitivity Tests</topic><topic>Microbial Viability - drug effects</topic><topic>Phage Therapy - veterinary</topic><topic>Phages</topic><topic>phage‐based therapy</topic><topic>Synergistic effect</topic><topic>Therapy</topic><topic>Zebrafish</topic><topic>ΦEcSw</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Easwaran, Maheswaran</creatorcontrib><creatorcontrib>De Zoysa, Mahanama</creatorcontrib><creatorcontrib>Shin, Hyun‐Jin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transboundary and emerging diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Easwaran, Maheswaran</au><au>De Zoysa, Mahanama</au><au>Shin, Hyun‐Jin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Application of phage therapy: Synergistic effect of phage EcSw (ΦEcSw) and antibiotic combination towards antibiotic‐resistant Escherichia coli</atitle><jtitle>Transboundary and emerging diseases</jtitle><addtitle>Transbound Emerg Dis</addtitle><date>2020-11</date><risdate>2020</risdate><volume>67</volume><issue>6</issue><spage>2809</spage><epage>2817</epage><pages>2809-2817</pages><issn>1865-1674</issn><eissn>1865-1682</eissn><abstract>Bacteriophage therapy is acknowledged as a potential tool to prevent or treat multidrug‐resistant bacterial infections. In this study, our major focus was on the bacteriolytic activity of phage EcSw (ΦEcSw) against the emergence of the clinically important Escherichia coli Sw1 and E. coli O157:H7. The amount of the antibiotics was changed in a concentration‐dependent manner, and the ΦEcSw susceptibility to antibiotics was determined. The kanamycin and chloramphenicol inhibited the titre of phage, but ampicillin did not show phage inhibition. Though the kanamycin and chloramphenicol controlled the growth of Sw1 in a concentration‐dependent manner, the ampicillin did not due to the resistance. The combined activity of the ΦEcSw with antibiotics (kanamycin and chloramphenicol) compared with the antibiotics alone showed significant lytic activity p < .001). In addition, phage‐based therapy was evaluated for controlling the multidrug‐resistant E. coli Sw1 and E. coli O157:H7 in zebrafish and BALB/c mice, respectively. Our results provide novel advantages of phage therapy and phage–antibiotic therapy to control antibiotic‐resistant bacteria.</abstract><cop>Germany</cop><pub>Hindawi Limited</pub><pmid>32453904</pmid><doi>10.1111/tbed.13646</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6805-4924</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1865-1674 |
| ispartof | Transboundary and emerging diseases, 2020-11, Vol.67 (6), p.2809-2817 |
| issn | 1865-1674 1865-1682 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2407312322 |
| source | Wiley-Blackwell Journals; MEDLINE |
| subjects | Ampicillin Ampicillin - therapeutic use Animals Anti-Bacterial Agents - therapeutic use Antibiotics Bacterial diseases Bacteriophages - physiology Chloramphenicol Chloramphenicol - therapeutic use Chloromycetin Combined Modality Therapy Drug Resistance, Multiple, Bacterial - drug effects E coli Escherichia coli Escherichia coli Infections - drug therapy Escherichia coli Infections - veterinary Escherichia coli O157 - drug effects Kanamycin Kanamycin - therapeutic use Mice Mice, Inbred BALB C Microbial Sensitivity Tests Microbial Viability - drug effects Phage Therapy - veterinary Phages phage‐based therapy Synergistic effect Therapy Zebrafish ΦEcSw |
| title | Application of phage therapy: Synergistic effect of phage EcSw (ΦEcSw) and antibiotic combination towards antibiotic‐resistant Escherichia coli |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A12%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Application%20of%20phage%20therapy:%20Synergistic%20effect%20of%20phage%20EcSw%20(%CE%A6EcSw)%20and%20antibiotic%20combination%20towards%20antibiotic%E2%80%90resistant%20Escherichia%20coli&rft.jtitle=Transboundary%20and%20emerging%20diseases&rft.au=Easwaran,%20Maheswaran&rft.date=2020-11&rft.volume=67&rft.issue=6&rft.spage=2809&rft.epage=2817&rft.pages=2809-2817&rft.issn=1865-1674&rft.eissn=1865-1682&rft_id=info:doi/10.1111/tbed.13646&rft_dat=%3Cproquest_cross%3E2468491270%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2468491270&rft_id=info:pmid/32453904&rfr_iscdi=true |